drugset
drugset / Trial / NCT06455917

TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients

NCT06455917 ↗

Phase 2 Recruiting 30 enrolled University Hospital, Basel, Switzerland
NaSingle-groupOpen-labelTreatment

Summary

Aim of the study is to investigate the efficacy and safety of adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) in patients with advanced pre-treated non-small cell lung cancer (NSCLC).

Timeline

Start
2025-01-22
Primary completion
2029-12
Completion
2029-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tumor Infiltrating Lymphocytes Cell therapy — Other

Indications

non-small cell lung carcinoma